MEDIFAST INC (MED) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:MED - US58470H1014 - Common Stock
10.68 USD
+0.26 (+2.5%)
10.68 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MED. MED was compared to 34 industry peers in the Personal Care Products industry. No worries on liquidiy or solvency for MED as it has an excellent financial health rating, but there are worries on the profitability. MED does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
MED had negative earnings in the past year.
In the past year MED had a positive cash flow from operations.
MED had positive earnings in each of the past 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED's Return On Assets of 0.09% is in line compared to the rest of the industry. MED outperforms 44.12% of its industry peers.
The Return On Equity of MED (0.12%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.09% | ||
| ROE | 0.12% | ||
| ROIC | N/A |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Profit Margin value of 0.06%, MED perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
MED's Profit Margin has declined in the last couple of years.
MED's Operating Margin has declined in the last couple of years.
The Gross Margin of MED (72.44%) is better than 73.53% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.06% | ||
| GM | 72.44% |
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
2. Health
2.1 Basic Checks
MED does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MED has been increased compared to 1 year ago.
The number of shares outstanding for MED has been reduced compared to 5 years ago.
MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.45 indicates that MED is not in any danger for bankruptcy at the moment.
MED has a better Altman-Z score (4.45) than 82.35% of its industry peers.
MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.45 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
MED has a Current Ratio of 4.45. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
MED has a Current ratio of 4.45. This is amongst the best in the industry. MED outperforms 88.24% of its industry peers.
MED has a Quick Ratio of 3.95. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MED (3.95) is better than 91.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.45 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
The earnings per share for MED have decreased strongly by -100.60% in the last year.
Measured over the past years, MED shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.59% on average per year.
The Revenue for MED has decreased by -36.29% in the past year. This is quite bad
MED shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.33% yearly.
EPS 1Y (TTM)-100.6%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-160%
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-36.21%
3.2 Future
MED is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -64.21% yearly.
The Revenue is expected to decrease by -23.25% on average over the next years. This is quite bad
EPS Next Y-146.27%
EPS Next 2Y-64.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
The rest of the industry has a similar Price/Free Cash Flow ratio as MED.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 181.69 | ||
| EV/EBITDA | -16.59 |
4.3 Compensation for Growth
A cheap valuation may be justified as MED's earnings are expected to decrease with -64.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.21%
EPS Next 3YN/A
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 9.97%, which is a nice return.
In the last 3 months the price of MED has falen by -25.26%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 7.43, MED pays a better dividend. On top of this MED pays more dividend than 97.06% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, MED pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
5.2 History
The dividend of MED decreases each year by -53.42%.
MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-53.42%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
78.63% of the earnings are spent on dividend by MED. This is not a sustainable payout ratio.
MED's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP78.63%
EPS Next 2Y-64.21%
EPS Next 3YN/A
10.68
+0.26 (+2.5%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners79.62%
Inst Owner Change7.91%
Ins Owners3.3%
Ins Owner Change16.91%
Market Cap117.37M
Revenue(TTM)429.69M
Net Income(TTM)248.00K
Analysts46.67
Price Target15.3 (43.26%)
Short Float %19.2%
Short Ratio12.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
Yearly Dividend0.07
Dividend Growth(5Y)-53.42%
DP78.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.85%
Min EPS beat(2)46.69%
Max EPS beat(2)199.01%
EPS beat(4)4
Avg EPS beat(4)115.44%
Min EPS beat(4)46.69%
Max EPS beat(4)199.01%
EPS beat(8)6
Avg EPS beat(8)95.11%
EPS beat(12)10
Avg EPS beat(12)87.15%
EPS beat(16)13
Avg EPS beat(16)70.51%
Revenue beat(2)2
Avg Revenue beat(2)7.01%
Min Revenue beat(2)5.26%
Max Revenue beat(2)8.75%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.13%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)3.21%
Revenue beat(12)11
Avg Revenue beat(12)3.67%
Revenue beat(16)14
Avg Revenue beat(16)3.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.27 | ||
| P/FCF | 181.69 | ||
| P/OCF | 16.32 | ||
| P/B | 0.55 | ||
| P/tB | 0.55 | ||
| EV/EBITDA | -16.59 |
EPS(TTM)-0.01
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)0.06
FCFY0.55%
OCF(TTM)0.65
OCFY6.13%
SpS39.1
BVpS19.54
TBVpS19.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.09% | ||
| ROE | 0.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.06% | ||
| GM | 72.44% | ||
| FCFM | 0.15% |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)57.45%
ROCE(5y)70.54%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 46.9% | ||
| Cap/Sales | 1.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 89.73% | ||
| Profit Quality | 260.48% | ||
| Current Ratio | 4.45 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 4.45 |
F-Score5
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)86.65%
Cap/Depr(5y)168.74%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.15%
Profit Quality(3y)359.98%
Profit Quality(5y)250.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-100.6%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-160%
EPS Next Y-146.27%
EPS Next 2Y-64.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-36.21%
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-120.14%
EBIT growth 3Y-55.18%
EBIT growth 5Y-26.54%
EBIT Next Year-105.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.63%
FCF growth 3Y-34.4%
FCF growth 5Y-25.51%
OCF growth 1Y-96.19%
OCF growth 3Y-36.26%
OCF growth 5Y-21.91%
MEDIFAST INC / MED FAQ
What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MED.
What is the valuation status for MED stock?
ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.
What is the profitability of MED stock?
MEDIFAST INC (MED) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for MED stock?
The Earnings per Share (EPS) of MEDIFAST INC (MED) is expected to decline by -146.27% in the next year.